Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Systematic characterisation of cellular localisation and expression profiles of proteins containing MHC ligands.

Juncker AS, Larsen MV, Weinhold N, Nielsen M, Brunak S, Lund O.

PLoS One. 2009 Oct 14;4(10):e7448. doi: 10.1371/journal.pone.0007448.

2.

Structure of peptides associated with class I and class II MHC molecules.

Engelhard VH.

Annu Rev Immunol. 1994;12:181-207. Review.

PMID:
7516668
3.

Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, Weissert R.

Mol Cell Proteomics. 2009 Sep;8(9):2090-101. doi: 10.1074/mcp.M900001-MCP200. Epub 2009 Jun 16.

4.

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7922-7. Epub 2005 May 13.

5.

[MHC tetramers: tracking specific immunity].

Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D.

Acta Med Croatica. 2003;57(4):255-9. Review. Croatian.

PMID:
14639858
7.

Immune selection in murine tumors. Ph.d thesis.

Svane IM, Engel AM.

APMIS Suppl. 2003;(106):1-46.

PMID:
12739251
9.

A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein.

Samino Y, López D, Guil S, Saveanu L, van Endert PM, Del Val M.

J Biol Chem. 2006 Mar 10;281(10):6358-65. Epub 2006 Jan 6.

10.

Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression.

Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD.

J Virol. 2006 Jan;80(2):951-63.

11.

Class II MHC molecules can use the endogenous pathway of antigen presentation.

Nuchtern JG, Biddison WE, Klausner RD.

Nature. 1990 Jan 4;343(6253):74-6.

PMID:
1967486
12.

[Processing of MHC class I presented antigens].

van Endert P.

Med Sci (Paris). 2006 Aug-Sep;22(8-9):727-32. Review. French.

13.

Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways.

Lippolis JD, Denis-Mize KS, Brinckerhoff LH, Slingluff CL Jr, Galloway DR, Engelhard VH.

Cell Immunol. 2000 Aug 1;203(2):75-83.

PMID:
11006005
14.

Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods.

Zhang H, Lundegaard C, Nielsen M.

Bioinformatics. 2009 Jan 1;25(1):83-9. doi: 10.1093/bioinformatics/btn579. Epub 2008 Nov 7.

15.

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.

16.

Non-conventional sources of peptides presented by MHC class I.

Starck SR, Shastri N.

Cell Mol Life Sci. 2011 May;68(9):1471-9. doi: 10.1007/s00018-011-0655-0. Epub 2011 Mar 10. Review.

17.

Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.

Zhou G, Ding ZC, Fu J, Levitsky HI.

J Immunol. 2011 Feb 15;186(4):2148-55. doi: 10.4049/jimmunol.1002917. Epub 2011 Jan 17.

18.

Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition.

Tellam J, Smith C, Rist M, Webb N, Cooper L, Vuocolo T, Connolly G, Tscharke DC, Devoy MP, Khanna R.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9319-24. doi: 10.1073/pnas.0801968105. Epub 2008 Jun 30.

19.

Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, Hadrup SR, van Esch WJ, Heemskerk MH, Ovaa H, Schumacher TN.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3825-30. doi: 10.1073/pnas.0709717105. Epub 2008 Feb 28.

20.

Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation.

Kao C, Daniels MA, Jameson SC.

Int Immunol. 2005 Dec;17(12):1607-17. Epub 2005 Nov 1.

PMID:
16263755

Supplemental Content

Support Center